Chatino. Although hallucinogenic Psilocybe species are abundant in low-lying areas of Mexico, most ceremonial use takes places in mountainous areas of elevations greater than . Guzmán suggests this is a vestige of Spanish colonial influence from several hundred years earlier, when mushroom use was persecuted by the Catholic Church. Research Psilocybin has been a subject of preliminary research since the early 1960s, when the Harvard Psilocybin Project evaluated the potential therapeutic value of psilocybin for personality disorders. Beginning in the 2000s decade, research on anxiety disorders, major depression, and various addictions was conducted. Psilocybin has been tested for its potential for developing prescription drugs to treat drug dependence, anxiety, or mood disorders. Psilocybin and LSD are under preliminary research as possible psychoplastogens. In 2018–2019, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatment-resistant depression and major depressive disorder, a review process enabling the FDA to implement an expedited review if clinical research results for psilocybin use in treating depression are compelling. A 2021 review found use of psilocybin was associated with reduced intensity of depression symptoms. See also List of entheogens O-Acetylpsilocin Psychoactive drug Psychedelic experience Psychedelic microdosing Psychedelic plants Soma (drink) Psychoplastogen Explanatory notes References Citations == External links == Psilocybin Investigator's Brochure Usona Institute, 2021 Psychedelic drugs Psychedelic tryptamines Entheogens Mycotoxins Tryptamine alkaloids Serotonin receptor agonists Organophosphates Phenol esters Novartis brands